- Home
- TDC vs LGND Comparison
TDC vs LGND Comparison
Compare TDC & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDC
- LGND
- Stock Information
- Founded
- TDC 1979
- LGND 1987
- Country
- TDC United States
- LGND United States
- Employees
- TDC N/A
- LGND N/A
- Industry
- TDC Computer Software: Prepackaged Software
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- TDC Technology
- LGND Health Care
- Exchange
- TDC Nasdaq
- LGND Nasdaq
- Market Cap
- TDC 2.3B
- LGND 2.1B
- IPO Year
- TDC 2007
- LGND 1992
- Fundamental
- Price
- TDC $22.68
- LGND $104.84
- Analyst Decision
- TDC Hold
- LGND Strong Buy
- Analyst Count
- TDC 9
- LGND 7
- Target Price
- TDC $30.00
- LGND $144.67
- AVG Volume (30 Days)
- TDC 1.0M
- LGND 100.4K
- Earning Date
- TDC 05-06-2025
- LGND 05-08-2025
- Dividend Yield
- TDC N/A
- LGND N/A
- EPS Growth
- TDC 241.18
- LGND N/A
- EPS
- TDC 1.41
- LGND N/A
- Revenue
- TDC $1,703,000,000.00
- LGND $181,488,000.00
- Revenue This Year
- TDC N/A
- LGND $16.47
- Revenue Next Year
- TDC $0.55
- LGND $19.44
- P/E Ratio
- TDC $16.14
- LGND N/A
- Revenue Growth
- TDC N/A
- LGND 53.40
- 52 Week Low
- TDC $18.43
- LGND $72.61
- 52 Week High
- TDC $38.45
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- TDC 60.86
- LGND 43.48
- Support Level
- TDC $21.30
- LGND $99.24
- Resistance Level
- TDC $22.46
- LGND $107.37
- Average True Range (ATR)
- TDC 0.61
- LGND 3.79
- MACD
- TDC 0.29
- LGND -0.42
- Stochastic Oscillator
- TDC 96.87
- LGND 29.47
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.